Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication

Allaire, Manon; Nahon, Pierre; Layese, Richard; Bourcier, Valérie; Cagnot, Carole; Marcellin, Patrick; Guyader, Dominique; Pol, Stanislas; Larrey, Dominique; Lédinghen, Victor de; Ouzan, Denis; Zoulim, Fabien; Roulot, Dominique; Tran, Albert; Bronowicki, Jean–Pierre; Zarski, Jean–Pierre; Riachi, Ghassan; Calès, Paul; Péron, Jean‐Marie; Alric, Laurent; Bourlière, Marc; Maury, Philippe; Blanc, Jean‐Frédéric; Abergel, Armand; Serfaty, Lawrence; Mallat, Ariane; Grangé, Jean‐Didier; Attali, P; Bacq, Yannick; Wartelle, Claire; Dao, Thông; Thabut, Dominique; Pilette, Christophe; Silvain, Christine; Christidis, Christos; Nguyen‐Khac, Eric; Bernard‐Chabert, Brigitte; Zucman, David; Martino, Vincent Di; Sutton, Angéla; Letouzé, Éric; Audureau, Étienne; Roudot‐Thoraval, Françoise

doi:10.1002/hep.30034

Cited by 37 publications

(33 citation statements)

References 25 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…79 Recently, an increased age-adjusted incidence of EHC was reported in French patients with HCV cirrhosis compared with that in the general population (standardised mortality ratio [SMR] 1.31; 95% CI 1.04-1.64). 80 This increase was even greater in those who had previously achieved SVR (SMR 1.57; 95% CI 1.08-2.22) (Fig. 2D).…”

Section: Extrahepatic Cancersmentioning

confidence: 85%

“…EHC was the leading cause of death in the CirVir cohort in patients who achieved SVR. Reproduced from Nahon et al, 14,57 Allaire et al 80 and Cacoub et al 75 with permission. BI, bacterial infection; DAA, direct-acting antiviral; EHCs, extrahepatic cancers; SVR, sustained virological response.…”

Section: Identification Of Cirrhotic Patients With a Higher Residual mentioning

confidence: 99%

See 1 more Smart Citation

Management of patients with pre-therapeutic advanced liver fibrosis following HCV eradication

Nahon

Ganne-Carrié

2019

JHEP Reports

Self Cite

View full text Add to dashboard Cite

Patients with HCV-related bridging fibrosis or cirrhosis remain at risk of developing lifethreatening complications even after achieving a sustained virological response. Although it is reduced, the risk of liver-related events in these patients justifies their inclusion in surveillance programmes dedicated to the early detection of hepatocellular carcinoma and the screening for portal hypertension. Biochemical parameters or non-invasive tests might indicate the potential progression of liver injury despite viral clearance. Specific attention must be focused on the management of comorbidities, while dedicated educational programmes must be encouraged to increase compliance and commitment to surveillance. Better knowledge of the long-term evolution of these patients, who now live longer, is essential to improve risk stratification and refine screening strategies in this growing population.

show abstract

Section: Extrahepatic Cancersmentioning

confidence: 85%

Section: Identification Of Cirrhotic Patients With a Higher Residual mentioning

confidence: 99%

Management of patients with pre-therapeutic advanced liver fibrosis following HCV eradication

Nahon

Ganne-Carrié

2019

JHEP Reports

Self Cite

View full text Add to dashboard Cite

show abstract

“…27 A recent study reported that patients with viral hepatitis have a 30% higher risk of extrahepatic cancer compared with the general population. 28 With the expected decline in liver-related complications during the era of antiviral agents, the improved longevity in individuals with viral hepatitis has been marred by rising mortality from extrahepatic complications, now representing the fourth most common cause of death in the overall cohort and the leading cause in patients with viral eradication (HCV infection) or adequate viral suppression (HBV infection). 28 Several studies have suggested that chronic HCV infection or chronic HBV infection increases the risk of hematologic malignancy, particularly non-Hodgkin lymphoma and myelodysplastic syndrome.…”

Section: Discussionmentioning

confidence: 99%

Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017

et al. 2019

View full text Add to dashboard Cite

BACKGROUND & AIMS: Trends of mortality associated with extrahepatic complications of chronic liver disease might be changing. We studied trends in mortality from extrahepatic complications of viral hepatitis, alcoholic liver disease (ALD), and nonalcoholic fatty liver disease in the United States. METHODS: We performed a population-based study using US Census and the National Center for Health Statistics mortality records from 2007 through 2017. We identified trends in age-standardized mortality using Joinpoint trend analysis with estimates of annual percent change. RESULTS: The liver-related mortality among patients with hepatitis C virus (HCV) infection increased from 2007 through 2013 and then decreased once patients began receiving treatment with direct-acting antiviral (DAA) agents, from 2014 through 2017. Among patients with HCV infection, the age-standardized mortality for extrahepatic cancers was 2.6%, for cardiovascular disease was 1.9%, and for diabetes was 3.3%. Among individuals with hepatitis B virus infection, liver-related mortality decreased steadily from 2007 through 2017. During the study, agestandardized mortality from hepatitis B virus-related extrahepatic complications increased by an average of 2.0% each year. Although liver-related mortality from ALD continued to increase, mortality from extrahepatic complications of ALD did not change significantly during the 11year study. Among patients with nonalcoholic fatty liver disease, the cause of death was most frequently cardiovascular disease, which increased gradually over the study period, whereas liver-related mortality increased rapidly. CONCLUSIONS: In an analysis of US Census and the National Center for Health Statistics mortality records, we found that after widespread use of DAA agents for treatment of viral hepatitis, cause-specific mortality from extrahepatic cancers increased, whereas mortality from cardiovascular disease or diabetes increased only among patients with HCV infection. These findings indicate the need to reassess risk and risk factors for extrahepatic cancer, cardiovascular disease, and diabetes in individuals successfully treated for HCV infection with DAA agents.

show abstract

“…[24][25][26] However, cirrhotic patients who achieve SVR remain at risk of developing hepatocellular carcinoma 27 and extrahepatic cancers. 28 Additionally, reversal of cirrhosis after SVR seems to be a slow process and the alterations of the immune system may persist after achieving SVR, particularly in cirrhotic patients. 20 Previous studies have described a significant decrease, after SVR with HCV therapy, in peripheral memory T-cells 29 and immune activation (CD4 + CD38 + and CD8 + CD38 + ), [29][30][31] and in plasma levels of biomarkers related to inflammation (interleukin (IL) −6, IFN-γ -inducible protein 10 (IP-10)), 32 bacterial translocation (lipopolysaccharide binding protein, soluble CD14 (sCD14) and fatty acid-binding protein 2 (FABP2)), 30 , 32 and endothelial dysfunction (soluble tumor necrosis factor receptor-1 (sTNF-R1), soluble intercellular adhesion molecule 1 (sICAM-1) and soluble vascular cell adhesion molecule 1 (sVCAM-1)).…”

Section: Introductionmentioning

confidence: 99%

Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: A prospective study

García-Broncano

Medrano

Berenguer

et al. 2020

Journal of Infection

View full text Add to dashboard Cite

Objective: There are a lack of consistency among articles in regards to the evolution of peripheral immune biomarkers after HCV therapy. We aimed to detect the most relevant changes in peripheral immune biomarkers among HIV/HCV-coinfected patients who achieved sustained virologic response (SVR) following peg-IFN-α/ribavirin therapy and to evaluate its normalization with respect to an HIV-monoinfected control group. Methods: We performed a prospective cohort study in 99 HIV/HCV-coinfected patients with samples at baseline (HIV/HCV-b-group) and at week 24 after SVR (HIV/HCV-f-group). We also used a control group of 39 HIV-monoinfected patients (HIV-group) negative for HCV and HBV infections, and who had undetectable HIV viral load and CD4 + > 500 cells/mm 3. Peripheral T cell subsets were assessed by flow cytometry and plasma biomarkers by immunoassays. Results: HIV/HCV-coinfected patients had higher values of in IL-10, IL-4, IP-10, IL-8, IL-1 β, IL-18, IL-6, IFN-γ , IL-12p70, TNF-α, sVCAM-1, sICAM-1, and sTNFR-1 than HIV control subjects, both at the beginning and at the end of follow-up. Moreover, three biomarkers (CD4 + CD38 + , telomere length, and IL-1RA) were

show abstract

Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication

Abstract: Compared to the general French population, HCV cirrhosis is associated with a higher risk of EHC and the first cause of death in patients with viral cirrhosis who achieve virological control/eradication. (Hepatology 2018).

Cited by 37 publications

References 25 publications

Management of patients with pre-therapeutic advanced liver fibrosis following HCV eradication

Management of patients with pre-therapeutic advanced liver fibrosis following HCV eradication

Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017

Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: A prospective study

Contact Info

Product

Resources

About